Dubnikov Sharon et al evaluated clinical outcome of CD19 CAR‐T cells manufactured from earlier leukapheresis (at first relapse) compared with standard leukapheresis (at second relapse or beyond) in diffuse large B‐cell lymphoma (DLBCL). Here, CD19 is linked to diffuse large B-cell lymphoma.